文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

修订版国际工作组-欧洲白血病网骨髓纤维化贫血缓解标准的建议

Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.
PubMed 文献 · Blood · 2024-01-01

针对骨髓纤维化新药涌现的背景,2013版国际工作组-欧洲白血病网(IWG-ELN)缓解标准核心作者受召集修订标准,纳入性别差异的血红蛋白 eligibility 阈值、基于限制性输血实践的输血依赖性贫血(TDA)新定义,并提供分层缓解标准。修订草案经更广泛国际专家反馈后形成2024版建议,提出TDA新定义(入组前12周内≥3单位)及性别特异性血红蛋白阈值(女性<10 g/dL、男性<11 g/dL),并保留12周筛选观察期要求。

要点

  • 2024版IWG-ELN建议将TDA定义为入组前12周内输血≥3单位
  • eligibility 血红蛋白阈值设为女性<10 g/dL、男性<11 g/dL
  • 缓解标准区分TDA与非TDA,并分主要与次要缓解,保留12周筛选观察期

核心结论

  • 2024版IWG-ELN建议提出性别特异性血红蛋白 eligibility 阈值、基于当前限制性输血实践的TDA新定义,以及结构简单、可检测疗效信号(次要缓解)并兼顾主要缓解的分层缓解标准。

研究设计与样本

  • 召集2013版IWG-ELN骨髓纤维化缓解标准核心作者修订文件,初稿经更广泛国际专家反馈后形成2024版建议。

主要发现

  • 新定义TDA为入组前12周内输血≥3单位。
  • eligibility 血红蛋白阈值定为女性<10 g/dL、男性<11 g/dL。
  • 缓解标准区分TDA与非TDA,并分主要缓解与次要缓解。
  • 保留治疗期间12周筛选观察期的要求。

关键数值与推荐

  • TDA定义:入组前12周内输血≥3单位。
  • eligibility 血红蛋白阈值:女性<10 g/dL,男性<11 g/dL。
  • 缓解标准分TDA与非TDA两类,各分主要缓解与次要缓解。
  • 保留12周筛选观察期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With emerging new drugs in myelofibrosis (MF), a robust and harmonized framework for defining the severity of anemia and response to treatment will enhance clinical investigation and facilitate interstudy comparisons. Accordingly, the lead authors on the 2013 edition of the International Working Group-European LeukemiaNet (IWG-ELN) response criteria in MF were summoned to revise their document with the intent to (1) account for gender-specific differences in determining hemoglobin levels for eligibility criteria; (2) revise the definition of transfusion-dependent anemia (TDA) based on current restrictive transfusion practices; and (3) provide a structurally simple and easy to apply response criteria that are sensitive enough to detect efficacy signals (minor response) and also account for major responses. The initial draft of the 2024 IWG-ELN proposed criteria was subsequently circulated around a wider group of international experts and their feedback incorporated. The proposed articles include new definitions for TDA (≥3 units in the 12 weeks before study enrollment) and hemoglobin thresholds for eligibility criteria (<10 g/dL for women and <11 g/dL for men). The revised document also provides separate (TDA vs non-TDA) and graded (major vs minor response) response criteria while preserving the requirement for a 12-week period of screening and observation on treatment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Barosi G, Passamonti F, et al. Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024. PMID: 39116296. doi:10.1182/blood.2024025802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。